Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: A new treatment paradigm?

Oncologist

Volumn 19, Issue 3, 2014, Pages 266-274

  Christians, Kathleen K ^a   Tsai, Susan ^a   Mahmoud, Anna ^a   Ritch, Paul ^a   Thomas, James P ^a   Wiebe, Lauren ^a   Kelly, Tracy ^a   Erickson, Beth ^a   Wang, Huamin ^b   Evans, Douglas B ^a   George, Ben ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Borderline resectable pancreas cancer; FOLFIRINOX; Neoadjuvant therapy; Pancreatic adenocarcinoma

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; ANOREXIA; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE COURSE; FEMALE; FOLLOW UP; GASTROINTESTINAL MALFORMATION; HUMAN; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PATHOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TUMOR BIOPSY; ADENOCARCINOMA; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84896486447     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0273     Document Type: Article

References (14)

1. Evans DB, Erickson BA, Ritch P. Borderline resectable pancreatic cancer: Definitions and the importance of multimodality therapy. Ann Surg Oncol 2010; 17: 2803-2805.
2. Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: Theimportance of this emerging stage of disease. J AmColl Surg 2008; 206: 833-846.
3. National Comprehensive Cancer Network. NCCN practice guidelines for pancreatic cancer, version 2. Available at http://www. nccn. org/professionals/physician_gls/recently_updated. asp.
4. Abrams RA, Lowy AM, O'Reilly EM et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1751-1756.
5. Callery MP, Chang KJ, Fishman EK et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
6. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
7. Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13: 1035-1046.
8. Evans DB, Christians KC, Foley WD. Pancreaticoduodenectomy (Whipple operation) and total pancreatectomy for cancer. In: Fischer JL, ed. Mastery of Surgery. 6th edPhiladelphia, PA: Wolters Kluwer/Lippincott Williams &Wilkins, 2012: 1445-1466.
9. Christians K, Evans DB. Pancreaticoduodenectomy and vascular resection: Persistent controversy and current recommendations. Ann Surg Oncol 2009; 16: 789-791.
10. EdgeSB, ByrdDR, ComptonCCetal. AJCCCancer StagingManual. 7th ed. New York, NY: Springer, 2010.
11. Evans DB, Rich TA, Byrd DR et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127: 1335-1339.
12. Dawson B, Trapp RG. Basic and Clinical Biostatistics. New York, NY: Lange Medical Books/McGraw-Hill, 2001: 211-232.
13. Evans DB, Crane CH, Charnsangavej C et al. The added value of multidisciplinary care for patients with pancreatic cancer. Ann Surg Oncol 2008; 15: 2078-2080.
14. Raut CP, Tseng JF, Sun CC et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246: 52-60.